Shots:

• The P-lll PENELOPE-B study involves the assessment of Ibrance vs PBO in addition to at least 5yrs. of standard adjuvant endocrine therapy in 1-250 women with HR+- HER2- eBC at high risk of recurrence who have the residual invasive disease after completing neoadjuvant CT
• The study did not meet its 1EPs of (iDFS) in women with eBC- no unexpected safety signals were observed. The trial is sponsored by the GBG as part of a clinical research collaboration with Pfizer and other study groups
• Ibrance is an oral inhibitor of CDKs 4 and 6 and is approved in 95+ countries and has been prescribed to ~340-000 patients globally
  
  ­ Ref: Pfizer | Image: TrialSite News